Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.

Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis.

<h4>Background</h4>Antiviral drugs have been recommended as prophylaxis for the reactivation of hepatitis B virus (HBV) infection in cancer patients undergoing chemotherapy. However, screening and antiviral prophylaxis for lung cancer remain controversial because of insufficient evidence...

Full description

Bibliographic Details
Main Authors:	Yu-Tuan Wu, Xin Li, Zi-Li Liu, Zhou Xu, Wei Dai, Ke Zhang, Jiu-Song Wu, Bilal Arshad, Kai-Nan Wu, Ling-Quan Kong
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0179680&type=printable

Similar Items

A Novel Antiviral Treatment of Hepatitis C Virus Reactivation in a Breast Cancer Patient Undergoing Chemotherapy
by: Yu-Tuan Wu, et al.
Published: (2017-01-01)

Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy
by: Xin Li, et al.
Published: (2018-04-01)

Hepatitis B reactivation prophylaxis in immune-suppressed patients
by: A. Torresin, et al.
Published: (2008-11-01)

Hepatitis B Reactivation in Immunosupressed Patients, Prophylaxis and Management
by: Ulfa Kholili, et al.
Published: (2017-08-01)

Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy
by: Shousheng Liu, et al.
Published: (2021-02-01)

The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: A meta-analysis
by: Jun-Ying Liu, et al.
Published: (2015-02-01)

A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
by: Wen-Chi Chen, et al.
Published: (2015-01-01)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
by: Idanna Innocenti, et al.
Published: (2022-02-01)

Impact of immunosuppression and chemotherapy on reactivation of Viral hepatitis
by: Fallahian Farahnaz, et al.
Published: (2010-01-01)

The compliance of doctors with viral hepatitis B screening and antiviral prophylaxis in cancer patients receiving cytotoxic chemotherapy using a hospital-based screening reminder system.
by: Wei-Chih Sun, et al.
Published: (2015-01-01)

Reactivation risk of Hepatitis B Virus in both HBsAg negative and HBcIgG positive patients with solid malignancy. Is antiviral prophylaxis really necessary?
by: Murat Araz, et al.
Published: (2019-06-01)

Antiviral therapy and prophylaxis of acute respiratory infections
by: L. V. Osidak, et al.
Published: (2016-04-01)

Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea
by: Donghoon Lee, et al.
Published: (2018-02-01)

Risk assessment and management of hepatitis B reactivation from direct-acting antivirals for hepatitis C
by: Maureen Whitsett, et al.
Published: (2019-06-01)

ADVANCES IN CHEMOTHERAPY AND PROPHYLAXIS OF MALARIA
by: White, N, et al.
Published: (1993)

Reactive myelopoiesis and FX-expressing macrophages triggered by chemotherapy promote cancer lung metastasis
by: Caijun Wu, et al.
Published: (2023-05-01)

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
by: Hsin-Wei Fang, et al.
Published: (2024-04-01)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
by: Ghweil AA, et al.
Published: (2019-04-01)

A Sleeping Giant: Late HBV Reactivation After Rituximab-Based Chemotherapy Despite Correct Prophylaxis
by: Nowicka AA, et al.
Published: (2024-12-01)

Ophthalmic antiviral chemotherapy : An overview
by: Athmanathan Sreedharan, et al.
Published: (1997-01-01)

P1507: A PREDICTIVE MODEL OF HERPES ZOSTER AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION: VZV REACTIVATION AFTER ANTIVIRAL PROPHYLAXIS DISCONTINUATION
by: Cheng-Jie Feng, et al.
Published: (2023-08-01)

Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy
by: Chan-Keng Yang, et al.
Published: (2016-02-01)

Severe hepatitis B reactivation during direct-acting antiviral treatment in “the absence” of hepatitis B surface antigen
by: Lydia Sastre, et al.
Published: (2019-02-01)

Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?
by: Yi-Hua Zhou, et al.
Published: (2023-11-01)

Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation
by: Kaiwen Chen, et al.
Published: (2018-08-01)

Modeling the impacts of influenza antiviral prophylaxis strategies in nursing homes
by: Casey Zipfel, et al.
Published: (2023-06-01)

Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
by: Duwe, Susanne C., et al.
Published: (2021-04-01)

A review on cytomegalovirus in patients with autoimmune inflammatory rheumatic diseases: Prevalence, clinical spectrum, treatment, and antiviral prophylaxis
by: Brianna Brianna, et al.
Published: (2024-03-01)

Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance
by: Panayiotis D. Ziakas, et al.
Published: (2009-07-01)

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis
by: Ping Li, et al.
Published: (2021-07-01)

Reply to: “Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?”
by: Philippa C. Matthews, et al.
Published: (2023-11-01)

Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy
by: Chunyan Yuan, et al.
Published: (2022-03-01)

Outcomes of lung transplantation from donors with hepatitis C viremia with outpatient initiation of antiviral therapy
by: Ciara M. Shaver, et al.
Published: (2024-02-01)

Current Trend in Antiviral Therapy for Chronic Hepatitis B
by: Rong-Nan Chien, et al.
Published: (2022-02-01)

Hepatitis B and/or C virus reactivation in patients receiving chemotherapy: An observational study
by: Navin Nayan, et al.
Published: (2024-10-01)

Antiviral prophylaxis for varicella zoster in immunocompromised patients (excluding haematological malignancies)
by: Chang, C, et al.
Published: (2009)

Use of Antiviral Prophylaxis in Influenza Outbreaks in Long Term Care Facilities
by: Allison McGeer, et al.
Published: (2000-01-01)

Antiviral prophylaxis is effective in reducing influenza outbreak severity in residential care
by: M. Dronavalli, et al.
Published: (2020-12-01)

Antiviral prophylaxis during pandemic influenza may increase drug resistance
by: Koch Daniel, et al.
Published: (2009-01-01)

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease
by: Eun Ae Kang, et al.
Published: (2022-07-01)